Oculis Holding AG OCS

Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life ZUG, Switzerland, October 1, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, is partnering with the National Multiple Sclerosis Society on its Campaign to End MS, as the industry part

ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announces that director Lionel Carnot will be resigning from the Board of Directors, effective today, after nearly a decade of dedicated service since 2017. Anthony Rosenberg, Chair of the Board, remarked: “On behalf of the B

The PIONEER program marks a key step toward potential first-in-class neuroprotection for optic neuritis and other neurological diseases, supported by positive Acuity Phase 2 data, FDA Breakthrough Therapy and EMA PRIME designations, and recent positive feedback from the FDA Neurology Division. Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, today annou

ZUG, Switzerland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company. Attachments Notification of managers' transaction - Anthony Rosenberg - 13 August 2026 RSU vest Notification of managers' transaction - Christina Ackermann - 13 August 2026 RSU vest Notification of managers' transaction - Arshad Khanani - 13 August 2026 RSU vest Notification of managers' transaction - Robert Warner - 13 August

Oculis Holding (OCS) has agreed to acquire all of Accure Therapeutics' worldwide development and com

Transaction will enhance Oculis’ strategic flexibility and ownership of Privosegtor while driving long-term value creationTransaction consideration includes $3.8 million up-front cash payment at closing and up to 2,050,000 Oculis ordinary shares subject to lockup release over a period of up to 2 years, or vesting upon achievement of development and regulatory milestonesPrivosegtor, a neuroprotective drug candidate, is currently being investigated in registrational trials with initial indications

Company pivot to neuro-ophthalmology continues with Privosegtor positioned as lead late-stage asset through the registrational PIONEER program with expansion potential in acute multiple sclerosis (MS) relapses following positive FDA pre-IND feedbackEnrollment progressing as planned in the PREDICT-1 genotype-based registrational trial of Licaminlimab in dry eye disease with all planned sites activated and >45% patients randomized Cash, cash equivalents, and short-term investments of $282.3 millio

ZUG, Switzerland, Aug. 03, 2026 (GLOBE NEWSWIRE) -- The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privosegtor in acute multiple sclerosis (MS) relapses, addressing a significant unmet medical needThe FDA confirmed that existing Privosegtor data can be cross-referenced for a new Investigational New Drug (IND) application in acute MS relapses, planned for submission in the fourth quarter of 2026Privosegtor, a novel neuroprotective candidate, continues

ZUG, Switzerland, July 2, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Conference. The Company will provide an overview and update of its innovative current late-stage portfolio. Key highlights inclu